ArticlePhysical and engineering sciences in medicine2023
A deep learning nomogram of continuous glucose monitoring data for the risk prediction of diabetic retinopathy in type 2 diabetes.
Article in Physical and engineering sciences in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- The Central Role of Oxidative Stress in Diabetic Retinopathy: Advances in Pathogenesis, Diagnosis, and Therapy.Diagnostics (Basel, Switzerland) · 2026Review
- Integration of artificial intelligence and wearable technology in the management of diabetes and prediabetes.NPJ digital medicine · 2025Article
- Universal nomogram for predicting referable diabetic retinopathy: a validated model for community and ophthalmic outpatient populations using easily accessible indicators.Frontiers in endocrinology · 2025Article
- DDLA: a double deep latent autoencoder for diabetic retinopathy diagnose based on continuous glucose sensors.Medical & biological engineering & computing · 2024Article
- Continuous glucose monitoring for the routine care of type 2 diabetes mellitus.Nature reviews. Endocrinology · 2024Review
- Continuous Glucose Monitoring: A Transformative Approach to the Detection of Prediabetes.Journal of multidisciplinary healthcare · 2024Article
- The application of artificial intelligence in diabetic retinopathy: progress and prospects.Frontiers in cell and developmental biology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Continuous glucose monitoring (CGM) data analysis will provide a new perspective to analyze factors related to diabetic retinopathy (DR). However, the problem of visualizing CGM data and automatically predicting the incidence of DR from CGM is still controversial. Here, we explored the feasibility of using CGM profiles to predict DR in type 2 diabetes (T2D) by deep learning approach. This study fused deep learning with a regularized nomogram to construct a novel deep learning nomogram from CGM profiles to identify patients at high risk of DR. Specifically, a deep learning network was employed to mine the nonlinear relationship between CGM profiles and DR. Moreover, a novel nomogram combining CGM deep factors with basic information was established to score the patients' DR risk. This dataset consists of 788 patients belonging to two cohorts: 494 in the training cohort and 294 in the testing cohort. The area under the curve (AUC) values of our deep learning nomogram were 0.82 and 0.80 in the training cohort and testing cohort, respectively. By incorporating basic clinical factors, the deep learning nomogram achieved an AUC of 0.86 in the training cohort and 0.85 in the testing cohort. The calibration plot and decision curve showed that the deep learning nomogram had the potential for clinical application. This analysis method of CGM profiles can be extended to other diabetic complications by further investigation.
Indexed as
Identifiers
37041318What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.